[go: up one dir, main page]

MX2018005046A - Metodo para producir flutemetamol. - Google Patents

Metodo para producir flutemetamol.

Info

Publication number
MX2018005046A
MX2018005046A MX2018005046A MX2018005046A MX2018005046A MX 2018005046 A MX2018005046 A MX 2018005046A MX 2018005046 A MX2018005046 A MX 2018005046A MX 2018005046 A MX2018005046 A MX 2018005046A MX 2018005046 A MX2018005046 A MX 2018005046A
Authority
MX
Mexico
Prior art keywords
flutemetamol
labeled compound
general formula
predetermined general
compound represented
Prior art date
Application number
MX2018005046A
Other languages
English (en)
Other versions
MX376470B (es
Inventor
Okumura Yuki
Tonoya Gota
Matsunami Tomoyuki
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of MX2018005046A publication Critical patent/MX2018005046A/es
Publication of MX376470B publication Critical patent/MX376470B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/64Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002Heterocyclic compounds
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Saccharide Compounds (AREA)
  • Ink Jet (AREA)

Abstract

Se proporciona un método para producir flutemetamol que incluye las etapas de: hacer reaccionar un compuesto precursor representado por una fórmula general predeterminada con un fluoruro radioactivo para obtener un compuesto etiquetado 18F representado por una fórmula general predeterminada; permitir una base fuerte para actuar sobre la mezcla de reacción de la etapa de arriba que contiene el compuesto precursor y el compuesto etiquetado 18F; después de la etapa de arriba, purificar el compuesto etiquetado 18F utilizando un cartucho de extracción de fase sólida de fase inversa; y remover un grupo protector para obtener [18F]flutemetamol.
MX2018005046A 2015-10-28 2016-10-17 Método para producir flutemetamol. MX376470B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015211413A JP6485914B2 (ja) 2015-10-28 2015-10-28 フルテメタモルの製造方法
PCT/EP2016/074840 WO2017071980A1 (en) 2015-10-28 2016-10-17 Method for producing flutemetamol

Publications (2)

Publication Number Publication Date
MX2018005046A true MX2018005046A (es) 2018-06-13
MX376470B MX376470B (es) 2025-03-07

Family

ID=57144967

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018005046A MX376470B (es) 2015-10-28 2016-10-17 Método para producir flutemetamol.

Country Status (12)

Country Link
US (1) US10472338B2 (es)
EP (1) EP3368518B1 (es)
JP (1) JP6485914B2 (es)
KR (1) KR102668514B1 (es)
CN (1) CN108137520B (es)
AU (1) AU2016344537B2 (es)
CA (1) CA2998985C (es)
ES (1) ES2766474T3 (es)
IL (1) IL258148B (es)
MX (1) MX376470B (es)
RU (1) RU2733398C2 (es)
WO (1) WO2017071980A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6485914B2 (ja) 2015-10-28 2019-03-20 日本メジフィジックス株式会社 フルテメタモルの製造方法
JP6770837B2 (ja) * 2016-06-28 2020-10-21 日本メジフィジックス株式会社 放射性フッ素標識有機化合物を製造する方法
US11318216B2 (en) 2017-06-23 2022-05-03 Nihon Medi-Physics Co., Ltd. Method for producing radiohalogen-labeled compound and method for producing radiopharmaceutical
GB201805253D0 (en) * 2018-03-29 2018-05-16 Ge Healthcare Ltd Ip Solid phase extraction
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1010280A3 (fr) * 1996-05-02 1998-05-05 Coincidence S A Procede et dispositif de synthese de 2-[18f] fluoro-2-deoxy-d-glucose.
GB0229686D0 (en) * 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
WO2006133732A1 (en) * 2005-06-17 2006-12-21 Advanced Accelerator Applications Process for synthesizing labelled compounds
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
EP2017258B1 (en) * 2006-05-11 2012-03-14 Nihon Medi-Physics Co., Ltd. Process for production of radioactive fluorine-labeled organic compound
PL2182988T3 (pl) 2007-08-30 2015-02-27 Ge Healthcare Ltd Kompozycja radiofarmaceutyczna
NZ600791A (en) * 2009-10-08 2014-02-28 Ge Healthcare Ltd Solid phase extraction purification technique
JP6485914B2 (ja) 2015-10-28 2019-03-20 日本メジフィジックス株式会社 フルテメタモルの製造方法

Also Published As

Publication number Publication date
AU2016344537B2 (en) 2020-09-17
US20190055207A1 (en) 2019-02-21
IL258148A (en) 2018-05-31
RU2733398C2 (ru) 2020-10-01
AU2016344537A1 (en) 2018-04-12
BR112018007545A2 (pt) 2018-10-23
WO2017071980A1 (en) 2017-05-04
MX376470B (es) 2025-03-07
RU2018113741A (ru) 2019-11-28
RU2018113741A3 (es) 2020-02-20
KR102668514B1 (ko) 2024-05-24
IL258148B (en) 2020-08-31
EP3368518B1 (en) 2019-12-04
US10472338B2 (en) 2019-11-12
CN108137520A (zh) 2018-06-08
ES2766474T3 (es) 2020-06-12
CA2998985A1 (en) 2017-05-04
CN108137520B (zh) 2022-06-21
HK1249098A1 (zh) 2018-10-26
JP2017081847A (ja) 2017-05-18
KR20180073581A (ko) 2018-07-02
EP3368518A1 (en) 2018-09-05
JP6485914B2 (ja) 2019-03-20
CA2998985C (en) 2023-10-31

Similar Documents

Publication Publication Date Title
MX2018005046A (es) Metodo para producir flutemetamol.
MX2016011527A (es) Metodo para recuperacion de vanadio y tungsteno a partir de una solucion de lixiviacion del catalizador de desnitrificacion de desecho.
CR20170564A (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20170163A7 (es) Compuestos derivados de d-fenilalanina-n-sustituido con biciclos aromáticos, método de preparación de las mismas y composiciones farmacéuticas que los contienen
CU20180073A7 (es) Nuevos derivados de amonio, un proceso para su preparación y composiciones farmacéuticas que los contienen
MX2020010330A (es) Proceso para preparar un compuesto antiviral de formula i.
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY36735A (es) Nuevos derivados hidroxiácido, un proceso para su preparación y composiciones farmacéuticas que los contienen
PE20180327A1 (es) Proceso para preparar 4-amino-piridazinas
MX392317B (es) Proceso para la preparación de etilenglicol a partir de azúcares.
AR105774A1 (es) Procedimiento para la preparación de (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridina-3-carboxamida y su purificación para su uso como principio activo farmacéutico
BR112019025028A2 (pt) Método para preparar um composto.
CU24366B1 (es) Compuestos que poseen un anillo que contiene nitrógeno salicílico unido a un grupo heteroarilo bicíclico útiles como inhibidores rorc2
MX2020004869A (es) Metodo para preparar derivado de benzofurano.
AR109669A1 (es) Proceso para preparar 2-exo-(2-metilbenciloxi)-1-metil-4-isopropil-7-oxabiciclo[2.2.1]heptano
MX2017011407A (es) Metodo para producir esteres de tetrahidropiranilo.
AR105812A1 (es) Métodos para la preparación de inhibidores de proteína deacetilasa
MX2018004223A (es) Un proceso para retirar compuestos de azufre de corrientes de proceso.
AR101136A1 (es) Proceso para la preparación de ácidos 3-hidroxipicolínicos
EA201491446A1 (ru) Способы получения пиперазинового пролекарства - ингибитора прикрепления вич
CL2008000299A1 (es) Procedimiento para preparar heptamolibdato de amonio que comprende a) agregar una fase organica conteniendo molibdeno a un aparato de re-extraccion liquido-liquido o de desorcion y agregar una solucion acuosa, y b) cristalizar directamente, por frio,
CO6470817A2 (es) Cristales de solvato novedosos
CL2017002759A1 (es) Método para crear un compuesto a base de mercurio, compuesto a base de mercurio, métodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
MX2019006959A (es) Procesos para la preparacion de compuestos de pirimidinilciclopentano.
WO2014115174A8 (en) Novel approach for synthesis of catechins

Legal Events

Date Code Title Description
FG Grant or registration